A paradigm shift in the 2020 ADA guidelines includes the earlier use of sodium glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2DM), especially those with heart failure (HF) and/or chronic kidney disease (CKD). Whether newly diagnosed or with a history of T2DM, treatment of any patient at high risk for or with established atherosclerotic cardiovascular disease, HF, or CKD should include an SGLT2 inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist, regardless of their glycated hemoglobin level or goal. In this activity, an expert in diabetes management discusses how therapy with SGLT2 inhibitors goes beyond glycemic control and explains why they are a preferred modality for patients with HF and/or CKD.
Clinical review and case study
After completing this activity, participants should be better able to:
- Describe evidence supporting use of SGLT2 inhibitors in the setting of existing CVD, HF, or renal disease
- Integrate SGLT2 inhibitors into the treatment plans of patients with T2DM according to evidence-based guidelines and patient-specific factors
- Implement patient-centered management for patients with T2DM within the context of current guidelines
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Mary Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, California
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until October 30, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Daniel Thibodeau, MHP, PA-C, Eastern Virginia Medical School, Norfolk, Virginia
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity was developed from a series of programs cosupported by educational grants from AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; Genentech, a member of the Roche Group; Novo Nordisk Inc.; Sanofi Genzyme; and Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Peters: advisory board: Boehringer Ingelheim, Eli Lilly and Company, MannKind, Merck, Sanofi; advisory board/research support: Abbott Diabetes Care; advisory board/speakers bureau: Novo Nordisk; advisory board/stock options: Livongo, Pendulum Therapeutics; research support: Dexcom, vTv Therapeutics; stock options: Mellitus Health, Omada Health, Stability Health.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: October 31, 2020
Expiration date: October 30, 2021
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97220CPCE-7C